King Rachel K.
Known title: DirectorCIK: 0001589712
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
CBIO Announces New Clinical Trial Milestones for CR-001. Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.
Transaction History
| NVAX | ▲ Buy | Option Exercise | 18,880 | — | 6/20/2026 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 10,420 | $0 | 6/12/2025 | View on chart |
| NVAX | ▼ Sell | Open Market | 4,150 | $37K | 12/13/2024 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 6,670 | $0 | 6/12/2024 | View on chart |
| CBIO | ▲ Buy | Grant | 3,334 | $10K | 3/29/2024 | View on chart |
| CBIO | ▲ Buy | Grant | 4,238 | $10K | 12/29/2023 | View on chart |
| CBIO | ▲ Buy | Grant | 6,667 | $10K | 9/30/2023 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 3,100 | — | 6/10/2023 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 700 | — | 6/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
NVAX Rallies 16% on NIH Cancer Vaccine Push Reports
Novavax shares surged 16% as part of a broader rally in vaccine stocks, driven by reports that the NIH is planning a major push for cancer vaccines. This news lifted the entire sector, with peers like Moderna and Merck also seeing significant gains. The move pushed NVAX into overbought territory, with its RSI reaching 68.6, though it remains below the average analyst target price.
NVAX Rallies 16% on NIH Cancer Vaccine Push Reports. Novavax shares surged 16% as part of a broader rally in vaccine stocks, driven by reports that the NIH is planning a major push for cancer vaccines. This news lifted the entire sector, with peers like Moderna and Merck also seeing significant gains. The move pushed NVAX into overbought territory, with its RSI reaching 68.6, though it remains below the average analyst target price.